Advaxis

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded on June 5, 1987 and is headquartered in Monmouth Junction, NJ.

Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA®

Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update

Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recently progressed on KEYTRUDA®

Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC

Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets

First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA®

Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

PRINCETON, N.J., Jan.  21, 2020  (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into a definitive agreement with two institutional investors for the purchase and sale of 10,000,000 shares of the Company’s common stock at an offering price of $1.05 per share, for gross proceeds of $10.5 million before deducting fees and other estimated offering expenses, pursuant to a registered direct offering (the “Offering”). The Company has also agreed to issue to those investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 5,000,000 shares of the Company’s common stock. The warrants will be exercisable on the six-month anniversary of issuance and will have a five-year term and an exercise price of $1.25 per share.

Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering

Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript

Nanocap Advaxis, Inc.  is seeing strength Wednesday following an announcement concerning its cervical cancer drug.

Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug

Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know

Is  (ADXS) Outperforming Other Medical Stocks This Year?

Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?

Equity offerings played a big role for two of these companies.

Why Advaxis Slumped Today

ADMA Biologics

Novartis

Roche Holding AG

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

Shares of Advaxis Inc. plummeted 25% to pace all premarket declines Wednesday, after the biotechnology company's public offering of shares priced at a deep discount.

Advaxis' stock plummets after public offering prices at deep discount

The small-cap biotech reported encouraging news about its prostate cancer therapy.

Why Advaxis Stock Skyrocketed 13.8% Today

Advaxis, Inc. has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days.

Advaxis Shares Surge After Positive Clinical Trial Updates

As of late, it has definitely been a great time to be an investor in Advaxis.

Will Advaxis Continue to Surge Higher?

This owner and operator of a late-stage biotechnology company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 days.

Top Ranked Momentum Stocks to Buy for March 25th: Advaxis, Inc.

Has Advaxis (ADXS) Outpaced Other Medical Stocks This Year?

News for Advaxis Stock (ADXS)